The safety of atypical antipsychotics: Does QTc provide all the answers?

Expert Opinion on Drug Safety

Volumn 10, Issue 3, 2011, Pages 341-344

  Nielsen, Jimmi ^a  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

antipsychotic; QTc; sertindole; T wave morphology; ziprasidone

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; FLECAINIDE; OLANZAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE;

AGRANULOCYTOSIS; CARDIOMYOPATHY; CAUSE OF DEATH; CIRCADIAN RHYTHM; DISEASE MARKER; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ELECTROCARDIOGRAPHY; HEART ARRHYTHMIA; HEART INFARCTION; HEART VENTRICLE EXTRASYSTOLE; HUMAN; MORTALITY; MYOCARDITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; QT DISPERSION; QT INTERVAL; QT PROLONGATION; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SUDDEN DEATH; T WAVE; TORSADE DES POINTES; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; HUMANS; LONG QT SYNDROME; PIPERAZINES; THIAZOLES; TORSADES DE POINTES;

EID: 79955413065     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.2011.576665     Document Type: Review

References (23)

1. Citrome L. Drug safety evaluation of Ziprasidone. Expert Opinion on Drug Safety 2011:10(3):429-40
2. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 2007;64(10):1123-31 (Pubitemid 47529346)
3. Tiihonen J, Lonnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009;374(9690):620-7
4. De Hert M, Correll CU, Cohen D. Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study. Schizophr Res 2010;117(1):68-74
5. Glassman AH, Bigger JT Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001;158(11):1774-82 (Pubitemid 33054769)
6. Epstein AE, Hallstrom AP, Rogers WJ, et al. Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction. The original design concept of the Cardiac Arrhythmia Suppression Trial (CAST). JAMA 1993;270(20):2451-5 (Pubitemid 23342294)
7. Porthan K, Viitasalo M, Jula A, et al. Predictive value of electrocardiographic QT interval and T-wave morphology parameters for all-cause and cardiovascular mortality in a general population sample. Heart Rhythm 2009;6(8):1202-8, 8 e1
8. Nielsen J, Andersen MP, Graff C, et al. The effect of sertindole on QTD and TPTE. Acta Psychiatr Scand 2010;121(5):385-8
9. Nielsen J, Graff C, Andersen MP, et al. Sertindole causes distinct electrocardiographic T-wave morphology changes. Eur Neuropsychopharmacol 2009;19(10):702-7
10. Graff C, Matz J, Christensen EB, et al. Quantitative analysis of T-wave morphology increases confidence in drug-induced cardiac repolarization abnormalities: evidence from the investigational IKr inhibitor Lu 35-138. J Clin Pharmacol 2009;49(11):1331-42
11. Strom BL, Eng SM, Faich G, et al. Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: the ziprasidone observational study of cardiac outcomes (ZODIAC). Am J Psychiatry 2011;168(2):193-201
12. Thomas SH, Drici MD, Hall GC, et al. Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP). Acta Psychiatr Scand 2010;122(5):345-55
13. Correll CU, Nielsen J. Antipsychotic-associated all-cause and cardiac mortality: what should we worry about and how should the risk be assessed? Acta Psychiatr Scand 2010;122(5):341-4
14. Cohle SD, Sampson BA. The negative autopsy: sudden cardiac death or other? Cardiovasc Pathol 2001;10(5):219-22 (Pubitemid 32982882)
15. Nielsen J, Skadhede S, Correll CU. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naive schizophrenia patients. Neuropsychopharmacology 2010;35(9):1997-2004
16. Nielsen J, le Quach P, Emborg C, et al. 10-Year trends in the treatment and outcomes of patients with first-episode schizophrenia. Acta Psychiatr Scand 2010;122(5):356-66
17. Vieweg WV, Wood MA, Fernandez A, et al. Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly. Drugs Aging 2009;26(12):997-1012
18. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353(12):1209-23 (Pubitemid 41345943)
19. Sicouri S, Antzelevitch C. Sudden cardiac death secondary to antidepressant and antipsychotic drugs. Expert Opin Drug Saf 2008;7(2):181-94 (Pubitemid 351447701)
20. Moore TA, Buchanan RW, Buckley PF, et al. The texas medication algorithm project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry 2007;68(11):1751-62 (Pubitemid 350247505)
21. Stauffer V, Ascher-Svanum H, Liu L, et al. Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials. BMC Psychiatry 2009;9:13
22. Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008;371(9618):1085-97 (Pubitemid 351418005)
23. Nielsen J, Dahm M, Lublin H, Taylor D. Psychiatrists attitude towards and knowledge of clozapine treatment. J Psychopharmacol 2010;24(7):965-71